GNS Healthcare Chosen to Present Discovery of New Clinical Predictors of Overall Survival in Metastatic Colorectal Cancer at ESMO 2019 in Collaboration with the Alliance for Clinical Trials in Oncology
AI-driven in silico patients used to identify heterogeneous landscape of clinical predictors of overall survival in populations of patients with metastatic colorectal cancer. CAMBRIDGE, Mass.– [July 2, 2019] – GNS Healthcare (GNS), a leading precision medicine company, together with the Alliance for Clinical Trials in Oncology (Alliance), is presenting discoveries of predictive biomarkers for metastatic colorectal cancer […]
GNS Healthcare Presents Results of Metastatic Colorectal Cancer Collaboration with the Alliance for Clinical Trials in Oncology at ESMO 2018
Study identifies clinical and molecular drivers of survival at baseline to allow better risk stratification at initiation of treatment CAMBRIDGE, Mass.– [October 22, 2018] – GNS Healthcare (GNS), a leading precision medicine company, presented results in metastatic colorectal cancer this week from their most recent collaboration with the Alliance for Clinical Trials in Oncology (Alliance) […]
Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in Metastatic Colorectal Cancer
Collaboration to apply causal artificial intelligence and clinical trial data to identify factors that drive treatment response in patients with metastatic colorectal cancer CAMBRIDGE, Mass.– September 6, 2018 – GNS Healthcare (GNS), a leading precision medicine company, announced a cross-industry partnership with Amgen and the Alliance for Clinical Trials in Oncology (Alliance) that will apply causal […]
GNS Healthcare and Alliance for Clinical Trials in Oncology Present Results of Causal Modeling that Identifies Clinical and Molecular Drivers of Survival in Colorectal Cancer Patients
Results presented at ASCO 2018 Annual Meeting in Chicago show drivers at baseline allow better risk stratification at initiation of treatment CAMBRIDGE, Mass- June 4, 2018 – GNS Healthcare (GNS), a leading precision medicine company, together with the Alliance for Clinical Trials in Oncology (Alliance), announced today the presentation of a poster supporting results that the […]